Prostate Cancer Management by Hormone Therapy May Increase the Risk of Neurological and Cardiac Disorders

Muhammad Imran Qadir

Institute of Molecular Biology & Biotechnology, Bahauddin Zakariya University, Multan, Pakistan

*Correspondence to: Dr. Muhammad Imran Qadir, Institute of Molecular Biology & Biotechnology, Bahauddin Zakariya University, Multan, Pakistan.

Copyright © 2018 Dr. Muhammad Imran Qadir. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The prostate is a gland in the male reproductive system that cause the production of fluid that forms the semen, the sperms are carried by this thick fluid.

With the advancement of men age, the prostate approximately unavoidably grows larger. This growth can hinder the urethra, due to this, men have to urinate more frequently or there may be difficulty with urine flow. Some patients take prescription drugs for this (Flomax being one of them) or herbal remedies (saw palmetto). Surgery is required to bring back flow in some severe cases. This is the situation when Prostate cancer is diagnosed [1].

Abiraterone, that’s chemical name is abiraterone acetate, also known as CB7630. It works another way as compare to other hormonal treatments for prostate cancer. It has an extensive range in blocking the release of enzyme CYP17, ultimately it prevents the testies and other tissues in the body to synthesize the testosterone.

Testosterone and estradiol are acknowledged as significant chemicals of our body and they play an important role in the nervous system along with sexual behavior. In numerous particular areas, cognitive performance was connected with dwindling when estradiol was used for therapeutic purpose. Patients were found to have momentary, minor but considerable decrease in visual recollection of figures and identification rate of numbers. The level of cognitive alteration was linked to the extent of estradiol decrease [2].

Hormonal treatment used for the management of prostate cancer causes an increased risk of cardiac disorders, not only limited to heart failure, arrhythmia (irregular heart beat), and ischemic heart disease, but also other related disorders [3].

The studies prove that the hormone therapy is the best treatment for prostate cancer. But there is a great disadvantage which is associated with the hormone therapy that is it can cause the fatal heart disease. Actually the hormone therapy can cause various changes in the body e.g. decrease in muscle weight, increase in body weight and body fat and also hormone treatments used to obstruct the effects of testosterone on prostate tumors can increase the risk of cardiac events and cardiac death. So the physician should be aware of these factors while treating the prostatic patient with the hormone therapy.

Bibliography

1. Baehr, T. (2003). Symptoms for prostate cancer. Prostate Cancer Journal, 72, 351-358.
2. Salminen, E. K., Portin, R. I., Koskinen, A., Helenius, H. & Nurmi, M. (2005). Estradiol and Cognition during Androgen Deprivation in Men with Prostate Carcinoma. Journal of the American Cancer Society, 103(7), 1381-1387.
3. Horig, H., Lee, C. S. & Kaufman, H. (2002). Prostate-specific antigen vaccines for prostate cancer. Expert Opin Biol Ther., 2(4), 395-408.